Effect of insulin on human skeletal muscle protein synthesis is modulated by insulin-induced changes in muscle blood flow and amino acid availability

Satoshi Fujita,1,3 Blake B. Rasmussen,2,4 Jerson G. Cadenas,1,3 James J. Grady,5 and Elena Volpi1,3
Departments of 1Medicine and 2Kinesiology and Biological Sciences, University of Southern California, Los Angeles, California; and Departments of 3Internal Medicine, 4Physical Therapy, and 5Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, Texas

Submitted 15 June 2005; accepted in final form 3 May 2006

Fujita, Satoshi, Blake B. Rasmussen, Jerson G. Cadenas, James J. Grady, and Elena Volpi. Effect of insulin on human skeletal muscle protein synthesis is modulated by insulin-induced changes in muscle blood flow and amino acid availability. Am J Physiol Endocrinol Metab 291: E745–E754, 2006. First published May 16, 2006; doi:10.1152/ajpendo.00271.2005.—Insulin promotes muscle anabolism, but it is still unclear whether it stimulates muscle protein synthesis in humans. We hypothesized that insulin can increase muscle protein synthesis only if it increases muscle amino acid availability. We measured muscle protein and amino acid metabolism using stable-isotope methodologies in 19 young healthy subjects at baseline and during insulin infusion in one leg at low (LD, 0.05), intermediate (ID, 0.15), or high (HD, 0.30 mU·min−1·100 ml−1) doses. Insulin was infused locally to induce muscle hyperinsulinemia within the physiological range while minimizing the systemic effects. Protein and amino acid kinetics across the leg were assessed using stable isotopes and muscle biopsies. The LD did not affect phenylalanine delivery to the muscle (−9 ± 18% change over baseline), muscle protein synthesis (16 ± 26%), breakdown, or net balance. The ID increased (P < 0.05) phenylalanine delivery (+63 ± 38%), muscle protein synthesis (+157 ± 54%), and net protein balance, with no change in breakdown. The HD did not change phenylalanine delivery (+12 ± 11%) or muscle protein synthesis (+9 ± 19%), and reduced muscle protein breakdown (−17 ± 15%), thus improving net muscle protein balance but to a lesser degree than the ID. Changes in muscle protein synthesis were strongly associated with changes in muscle blood flow and phenylalanine delivery and availability. In conclusion, physiological hyperinsulinemia promotes muscle protein synthesis as long as it concomitantly increases muscle blood flow, amino acid delivery and availability.

Insulin is a potent anabolic stimulus for muscle proteins. Insulin deficiency leads to a protein catabolic state with loss of muscle mass that can only be reversed by insulin therapy (1). Nonetheless, the mechanisms by which insulin enhances muscle protein anabolism are still debated. A stimulatory effect of insulin on protein synthesis has been demonstrated in various tissues, including skeletal muscle (16, 35, 37, 38). Furthermore, in vitro animal studies and a recent human experiment have shown that insulin can acutely stimulate muscle protein synthesis by increasing the initiation of mRNA translation (18, 23–25). On the other hand, if the physiological increase in insulin secretion is pharmacologically suppressed during feeding in rats, the stimulation of translation initiation is abolished and muscle protein synthesis suppressed (40). Insulin can also reduce protein breakdown by stabilizing lysosomes and reducing the activity of the ubiquitin-proteasome pathway (9, 15, 27).

In human subjects, insulin infusion induces net amino acid uptake across a limb (forearm or leg), an indication of net muscle protein anabolism, but the mechanisms are still unclear (4, 5, 14, 17, 19, 20, 28, 32–34, 53). About half of these studies reported that this effect was due to an increase in protein synthesis with no major changes or some reduction in proteolysis (4, 5, 20, 33, 34, 53). Conversely, the other studies found a significant reduction in protein degradation with no significant changes in protein synthesis (14, 17, 19, 28, 32). Because these experiments were performed using comparable stable-isotope arteriovenous balance methodologies, it is unlikely that technical or methodological problems were responsible for the conflicting findings. A review of these studies suggests that these apparent discrepancies on the metabolic mechanisms by which insulin stimulates muscle protein anabolism might be explained by differences in amino acid availability for the muscle tissue (55). Specifically, all studies in which muscle protein synthesis had been stimulated by insulin also had an increased amino acid delivery to the muscle tissue (amino acid concentration × blood flow) (4, 5, 18, 20, 33, 34, 53), whereas most studies reporting a decrease in muscle protein breakdown with no increase in synthesis during insulin infusion also had a decrease or no change in amino acid delivery (14, 19, 28, 32). The differences in amino acid delivery were mainly due to differences in amino acid concentrations, which, in turn, were determined by the modality of insulin infusion (systemic or local) and/or the concomitant infusion of exogenous amino acids. This is because systemic insulin infusion decreases blood amino acid concentrations (13, 14, 29, 32, 34, 45) unless amino acids are replaced by exogenous infusion (18–20, 32–34). Conversely, local insulin infusion in a leg or a forearm allows for the exposure of the muscle tissue to relatively high insulin levels while avoiding a major reduction in blood amino acid concentration (5, 28).

The current study was conducted to determine whether the response of muscle protein synthesis to insulin depends on insulin-induced changes in amino acid delivery and availability for the muscle tissue. To test this hypothesis, we induced local hyperinsulinemia in one leg in the absence of amino acid infusion. We used three physiological insulin doses (low, intermediate, and high) selected to either avoid a significant reduction in the systemic amino acid concentrations (the two lower doses) (5) or allow amino acids to decrease due to...
systemic hyperinsulinemia (higher dose) (13). Because the reduction in amino acid concentration was expected to occur at the highest insulin dose, this design allowed us to determine the relative contribution of insulin dose and amino acid availability on the response of muscle protein synthesis to insulin. This design was preferred to a fixed systemic insulin infusion with and without amino acid replacement because previous data indicate that available amino acid solutions for intravenous infusion cannot exactly replace all essential amino acids and maintain the baseline physiological pattern (12, 18). This is a major problem because it is known that essential amino acids can independently stimulate muscle protein synthesis (3, 49). Thus, if the amino acid replacement infusion delivered excessive amounts of certain essential amino acids, it would be impossible to distinguish between the effect of insulin and that of the amino acid infusion. In contrast, incomplete replacement of some amino acids could be responsible for an incomplete muscle protein synthesis response, again making data interpretation very difficult. Finally, the amino acid dose necessary to maintain the baseline concentrations would be significant (≈0.8 mg·kg⁻¹·min⁻¹) (12), so that over 3 h it could reach ≈10–11 g per subject, an amount that can stimulate muscle protein synthesis even in the absence of hyperinsulinemia (36).

SUBJECTS AND METHODS

Subjects. We studied 19 young subjects (11 men and 8 women) from the Los Angeles metropolitan area. All subjects were healthy and physically active, but they were not engaged in an exercise training program. Screening of subjects was performed with clinical history, physical examination, and laboratory tests, including complete blood count with differential, liver, and kidney function tests, coagulation profile, fasting blood glucose and oral glucose tolerance test (OGTT), hepatitis B and C screening, HIV test, TSH, lipid profile, pregnancy test in women, urinalysis, drug screening test, and electrocardiogram. Only subjects with screening results within the normal limits were randomly assigned to one of three groups according to the dose of insulin infused during the experiment: low dose (LD), intermediate dose (ID), and high dose (HD). The doses were chosen to increase insulin concentrations in the femoral vein within the physiological postprandial range (5, 13, 50). We did not include a fourth group infused with saline because we have found in a separate experiment that muscle protein metabolism is unaffected by time alone over the short term (6 h; data not shown). The subjects’ characteristics are summarized in Table 1.

<table>
<thead>
<tr>
<th></th>
<th>LD</th>
<th>ID</th>
<th>HD</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>6</td>
<td>7</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td>M 2 F</td>
<td>M 4 F</td>
<td>M 2 F</td>
<td>0.60</td>
</tr>
<tr>
<td>Age, yr</td>
<td>29±3</td>
<td>25±2</td>
<td>28±2</td>
<td>0.51</td>
</tr>
<tr>
<td>Height, cm</td>
<td>169±5</td>
<td>169±4</td>
<td>170±2</td>
<td>0.99</td>
</tr>
<tr>
<td>Body weight, kg</td>
<td>72±7</td>
<td>63±6</td>
<td>74±5</td>
<td>0.44</td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
<td>25±2</td>
<td>22±1</td>
<td>26±2</td>
<td>0.19</td>
</tr>
<tr>
<td>Fat-free mass, kg</td>
<td>50±4</td>
<td>45±5</td>
<td>54±3</td>
<td>0.30</td>
</tr>
<tr>
<td>Fat mass, kg</td>
<td>18±4</td>
<td>11±1</td>
<td>17±3</td>
<td>0.21</td>
</tr>
<tr>
<td>Leg volume, liters</td>
<td>9.5±1</td>
<td>8.4±5.9</td>
<td>9.9±3.5</td>
<td>0.33</td>
</tr>
<tr>
<td>Leg muscle mass, kg</td>
<td>8.6±8.9</td>
<td>7.3±8.9</td>
<td>9.9±3.3</td>
<td>0.21</td>
</tr>
</tbody>
</table>

Values are means ± SE. Subjects were randomized to 3 groups receiving a low (LD), intermediate (ID), or high dose (HD) insulin infusion. P, significance level for differences between groups.

Study design. The protocol was designed to measure muscle protein and amino acid and glucose kinetics in the postabsorptive basal state (0–240 min) and during insulin infusion (240–420 min). The night before the study, each subject was admitted to the General Clinical Research Center of the University of Southern California. At admission, a pregnancy test was repeated in women, and a dual-energy X-ray absorptiometry (DEXA) scan (QDR 4500W; Hologic, Bedford, MA) was performed to measure muscle mass. The subjects were then fed a standard dinner, and a snack was given at 2200. After 2200, the subjects were allowed only water ad libitum until the end of the experiment. The morning of the study, polyethylene catheters were inserted into a forearm vein for tracer and dextrose infusion, in a contralateral hand or wrist vein for arterialized blood sampling, and in the femoral artery and vein of one leg for blood sampling. The arterial catheter was also used for the infusion of insulin and indocyanine green (ICG; Akorn, Buffalo Grove, IL).

At 0730, after drawing of a blood sample for the measurement of background phenylalanine and glucose enrichments and ICG concentration, a primed continuous infusion of L-[ring-13C]phenylalanine and D-[6,6-2H2]glucose (Cambridge Isotope Laboratories, Andover, MA) was started and maintained at a constant rate until the end of experiment. The following priming doses (PD) and infusion rates (IR) were used: L-[ring-13C]phenylalanine: PD 2 μmol/kg, IR 0.05 μmol·kg⁻¹·min⁻¹; D-[6,6-2H2]glucose: PD 19 μmol/kg, IR 0.22 μmol·kg⁻¹·min⁻¹.

At 120 min, a first muscle biopsy was taken from the lateral portion of the vastus lateralis of the leg with the femoral catheters, using a 5-mm Bergström biopsy needle, using sterile procedure and local anesthesia with 1% Lidocaine injected subcutaneously and on the fascia. The muscle sample (150–400 mg) was rinsed with ice-cold saline and blotted, any visible fat or connective tissue was quickly removed, and it was immediately frozen in liquid nitrogen and stored at −80°C until analysis.

At 170 min, the continuous infusion of ICG was started in the femoral artery (0.5 mg/min) and maintained until 210 min. During ICG infusion, blood samples were taken four times at 10-min intervals from the femoral vein and the hand vein to measure ICG concentration. Subsequently, between 210 and 240 min, four blood samples were taken from the femoral artery and vein and from the hand vein to measure femoral arterial and venous phenylalanine and glucose concentrations and enrichments, femoral vein insulin concentration, and systemic insulin concentration (hand vein samples). At 240 min, a second muscle biopsy was taken as previously described.

Immediately after the second biopsy at 240 min, an insulin infusion was initiated into the femoral artery. The following infusion rates were used: LD 0.05 μU·min⁻¹·100 ml⁻¹ (0.06 μU·kg⁻¹·min⁻¹); ID 0.15 μU·min⁻¹·100 ml⁻¹ (0.2 μU·kg⁻¹·min⁻¹); and HD 0.30 μU·min⁻¹·100 ml⁻¹ (0.4 μU·kg⁻¹·min⁻¹). After the start of the insulin infusion, blood samples (0.5 ml) were taken every 5–10 min to monitor the plasma glucose concentration. Dextrose (20%) containing 2% D-[6,6-2H2]glucose was then infused at variable rate as necessary to clamp the plasma glucose concentration at the basal value. Glucose tracer was added to the dextrose to maintain the plasma glucose enrichment constant during the euglycemic hyperinsulinemic clamp.

Between 350 and 390 min, ICG was again infused to measure leg blood flow, and blood samples were taken between 350 and 390 min and 390 and 420 min, as described for the basal period. At 420 min, before the tracer and insulin infusion were stopped, a third muscle biopsy was taken, as described above.

Analytic methods. Plasma insulin concentrations were determined by radioimmunoassay (Linco Research, St. Charles, MO).

Serum ICG concentration for the determination of leg blood flow was measured spectrophotometrically (Beckman Coulter, Fullerton, CA) at λ = 805 nm (21, 22).

Plasma glucose concentration was measured using an automated glucose analyzer (YSI, Yellow Springs, OH). Enrichment of plasma glucose was determined on its pentaacetate derivative using gas-
Concentrations and enrichments of blood phenylalanine were determined by GC-MS after previously described (54). Intracellular free concentrations and concentrations in the femoral artery and vein, respectively; $E_t$ and $E_v$ are phenylalanine enrichments, expressed as tracer-to-tracee ratio, in the femoral arterial and venous plasma, respectively; and $BF$ is leg blood flow as calculated from the steady-state ICG concentration values in the femoral and wrist veins, as previously described (21, 22). Data were expressed per 100 ml of leg volume.

The specific parameters of the three-pool model were calculated as follows:

\[
\text{muscle inward transport} = F_{MA} = \left[ (C_A - C_v) / (E_A - E_v) \right] \cdot BF
\]

\[
\text{muscle outward transport} = F_{VM} = \left[ (C_A - C_v) / (E_A - E_v) \right] \cdot BF
\]

\[
\text{arteriovenous shunting} = F_{VA} = F_M - F_{MA}
\]

\[
\text{muscle protein breakdown} = F_{MB} = F_{MA} \cdot \left[ (E_v / E_m) - 1 \right]
\]

\[
\text{muscle protein synthesis} = F_{OM} = F_{MO} + NB \cdot E_m
\]

where $E_m$ is phenylalanine enrichment, expressed as tracer-to-tracee ratio, in the muscle.

Additionally, we calculated the intracellular phenylalanine availability as the sum of transport into the muscle $F_{MA}$ and the intracellular $R_v$ from breakdown $F_{MB}$:

\[
\text{intracellular phenylalanine availability} = F_{MA} + F_{MB}
\]

We also calculated the fractional synthetic rate (FSR) of mixed muscle proteins by measuring the incorporation rate of the phenylalanine tracer into the proteins ($\Delta F_p / t$) and using the precursor-product model to calculate the synthesis rate as follows (47):

\[
\text{FSR} = (\Delta E_p / t) \cdot \left[ (E_{M1} + E_{M2}) / 2 \right] \cdot 60 \cdot 100
\]

where $\Delta E_p$ is the increment in protein-bound phenylalanine enrichment between two sequential biopsies, $t$ is the time between the two sequential biopsies, and $E_{M1}$ and $E_{M2}$ are the phenylalanine enrichments in the free tissue pool in the two sequential biopsies. Data were expressed as per kilogram of body weight.

Although the use of free tissue enrichment may lead to an under-estimation of protein synthesis compared with tRNA (46), Miller et al. (31) have shown, using the microdialysis technique, that the rate-limiting factor for the exchange of amino acids between extra- and intracellular compartments is the transport from the blood into the extracellular compartment. Thus tissue enrichment can be safely used to estimate muscle protein FSR.

Steady-state whole body glucose $R_g$, which is equal to its utilization rate ($R_u$), was calculated using the single-pool model (54):

\[
R_u = R_d = I / E_g
\]

where $I$ is the tracer infusion rate and $E_g$ is the arterial glucose enrichment. During the clamp, the endogenous glucose $R_g$ was calculated by subtracting the exogenous glucose infusion from the total $R_u$. Data were reported per kilogram of body weight.

Leg glucose utilization was calculated as net glucose uptake across the leg:

\[
\text{leg glucose NB} = (C_{gA} - C_{gV}) \cdot BF
\]

where $C_{gA}$ and $C_{gV}$ are the plasma phenylalanine concentrations in the femoral artery and vein, respectively.

To determine the degree of muscle tissue exposure to insulin, we calculated the insulin delivery rate to the leg. This is because a small portion of the insulin directly infused into the leg was recycled through the systemic circulation back into the leg, thus increasing the amount of insulin delivered to the muscle. Additionally, since changes in leg blood flow can significantly affect insulin concentration when the exogenous infusion is constant, insulin concentration alone may not reflect the actual insulin availability for the muscle tissue. Because
Table 2. Insulin and glucose concentrations and kinetics

<table>
<thead>
<tr>
<th></th>
<th>LD Basal</th>
<th>LD Insulin</th>
<th>ID Basal</th>
<th>ID Insulin</th>
<th>HD Basal</th>
<th>HD Insulin</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Insulin</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Concentrations, μU/ml</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Femoral vein</td>
<td>10.6 ± 1.5</td>
<td>30.9 ± 7.7*</td>
<td>10.6 ± 1.2</td>
<td>45.8 ± 5.3*</td>
<td>6.7 ± 0.9</td>
<td>84.5 ± 5.0*</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Hand vein</td>
<td>9.9 ± 1.6</td>
<td>15.0 ± 2.1*</td>
<td>12.1 ± 0.4</td>
<td>17.4 ± 2.5ab</td>
<td>6.4 ± 1.1</td>
<td>19.1 ± 2.4*</td>
<td>0.03</td>
</tr>
<tr>
<td><strong>Leg insulin</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kinetics, μU/min⁻¹·100 ml leg volume⁻¹</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Femoral vein</td>
<td>33.6 ± 4.7</td>
<td>86.9 ± 20.5**</td>
<td>42.3 ± 6.8</td>
<td>282.1 ± 25.4**</td>
<td>24.5 ± 4.2</td>
<td>411.7 ± 57.6*</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Artery</td>
<td>5.13 ± 0.23</td>
<td>4.98 ± 0.18</td>
<td>4.88 ± 0.13</td>
<td>4.84 ± 0.13</td>
<td>4.76 ± 0.08</td>
<td>4.74 ± 0.14</td>
<td>0.59</td>
</tr>
<tr>
<td>Vein</td>
<td>5.02 ± 0.24</td>
<td>4.84 ± 0.19</td>
<td>4.79 ± 0.13</td>
<td>4.55 ± 0.15</td>
<td>4.66 ± 0.08</td>
<td>4.27 ± 0.14*</td>
<td>0.42</td>
</tr>
<tr>
<td><strong>Glucose</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Concentrations, mmol/l</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Artery</td>
<td>2.3 ± 0.2</td>
<td>2.9 ± 0.2*</td>
<td>2.0 ± 0.1</td>
<td>2.9 ± 0.1*</td>
<td>2.3 ± 0.2</td>
<td>3.1 ± 0.1*</td>
<td>0.0181</td>
</tr>
<tr>
<td>Vein</td>
<td>2.6 ± 0.2</td>
<td>2.9 ± 0.2*</td>
<td>2.0 ± 0.1</td>
<td>2.9 ± 0.1*</td>
<td>2.3 ± 0.2</td>
<td>3.1 ± 0.1*</td>
<td>0.0181</td>
</tr>
<tr>
<td><strong>Whole body</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose kinetics, μmol·kg⁻¹·min⁻¹</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endogenous $R_a$</td>
<td>9.95 ± 0.68</td>
<td>7.93 ± 0.52*</td>
<td>11.24 ± 0.75</td>
<td>7.71 ± 0.32*</td>
<td>10.08 ± 0.87</td>
<td>7.07 ± 0.31*</td>
<td>0.12</td>
</tr>
<tr>
<td>$R_d$</td>
<td>9.95 ± 0.68</td>
<td>11.76 ± 1.08**</td>
<td>11.24 ± 0.75</td>
<td>18.35 ± 0.88**</td>
<td>10.08 ± 0.87</td>
<td>22.16 ± 3.76**</td>
<td>0.004</td>
</tr>
<tr>
<td><strong>Leg glucose</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kinetics, μmol·min⁻¹·100 ml leg volume⁻¹</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net balance</td>
<td>0.36 ± 0.11</td>
<td>0.39 ± 0.13*</td>
<td>0.29 ± 0.09</td>
<td>1.57 ± 0.35**</td>
<td>0.33 ± 0.06</td>
<td>2.21 ± 0.34**</td>
<td>0.0003</td>
</tr>
</tbody>
</table>

Values are means ± SE. Insulin concentrations in the femoral and hand vein and delivery to the leg; glucose concentrations in the femoral artery and vein, enrichment in the femoral artery, whole body endogenous rate of appearance (endogenous $R_a$), utilization rate ($R_d$), and leg uptake (net balance) at baseline and during LD, ID, and HD insulin infusions in the leg. $P$, significance value for 1-way ANOVA on effect of insulin dose on changes from baseline, *$P < 0.05$ vs. basal (paired $t$-test). Common letter denotes that changes from baseline do not differ between groups (Tukey’s test).

The arterial insulin concentration was not measurable during insulin infusion because the infusion was administered through the arterial catheter, insulin delivery to the leg was estimated by multiplying the insulin concentration in the femoral vein (InsFV) by the blood flow:

\[
\text{insulin delivery} = \text{InsFV} \cdot BF \quad (16)
\]

Although this method may slightly underestimate the insulin delivery rate because some insulin is taken up by the muscle cells after binding the insulin receptor and does not return in the venous blood, for the reasons listed above we found it preferable to relying only on the calculated insulin dose as assessed at the time of infusion.

Statistical analysis. Subjects’ characteristics were analyzed using one-way analysis of variance (ANOVA) with the exception of sex, a categorical variable, which was analyzed using a $\chi^2$ test. Differences between baseline values for all measured variables were analyzed using one-way ANOVA. The effects of each insulin dose on the response variables were assessed using the paired $t$-test. The effect of the three insulin doses on the response variables was assessed on the changes from baseline values by one-way ANOVA. Post hoc tests were performed using the Tukey-Kramer test. The effect of the treatments on the changes in leg blood flow was analyzed using the Kruskal-Wallis test (using exact methods) because the change scores failed a test for normality. The Pearson product-moment correlation was used to assess associations between continuous variables reported. Stepwise regression analysis was performed using the step forward method. Differences were considered significant at $P < 0.05$. $P$ for trend was set at $<0.10$ and $>0.05$. Data are expressed as means ± SE.

RESULTS

Subjects’ characteristics. The demographic and physical characteristics of the subjects were not different among the groups (LD, ID, and HD; Table 1).

Blood flow. Baseline leg blood flow was not different between the groups (LD 3.31 ± 0.45, ID 4.03 ± 0.43, and HD 3.56 ± 0.40 ml·min⁻¹·100 ml leg volume⁻¹). During insulin infusion, leg blood flow was LD 2.90 ± 0.29, ID 6.69 ± 1.27, HD 4.73 ± 0.56 ml·min⁻¹·100 ml leg volume⁻¹. After the (post/pre) change scores failed Shapiro-Wilk’s test of normality ($P = 0.001$), the Kruskal-Wallis test indicated differences between the groups ($P = 0.04$). Pairwise comparisons indicated significant differences between LD and HD ($P = 0.026$) and between LD and ID ($P = 0.05$) but not between ID and HD ($P = 0.83$).

Insulin and glucose concentrations and kinetics. The results of insulin and glucose concentrations and kinetics are summarized in Table 2. There were no basal differences in femoral or systemic (hand) vein insulin concentrations among the three groups. Insulin infusion significantly increased both femoral and systemic vein insulin concentrations in all groups ($P < 0.05$), with the largest changes occurring in the HD group and the smallest changes in the LD group ($P < 0.05$).

Insulin delivery to the leg was not different among the three groups during the basal period. Insulin infusion increased the insulin delivery to the leg in all groups but to a different extent according to the dose: ~3-fold in the LD group, ~7-fold in ID group, and ~17-fold in HD group.

Plasma arterial and venous glucose concentrations were not different in the three groups during the basal period. During insulin infusion, the arterial glucose concentration did not change from baseline as a result of the glucose clamp, whereas the venous glucose concentrations significantly decreased in the HD group; however, the (post/pre) change scores did not differ between groups.

Arterial glucose enrichments were at steady state during the last hour of each study period and were not different among the three groups in the basal period. During insulin infusion, arterial glucose enrichments increased significantly ($P < 0.01$) in all three groups, with a larger change in the ID and HD groups ($P < 0.05$).
Enrichments in the muscle tissue did not change significantly in P changes occurring in the LD group (phenylalanine enrichment in the vein increased significantly in a dose-dependent manner, with the group differences. Phenylalanine enrichment in the artery significantly increased in all groups, with no differences among the groups. Net leg glucose uptake (net balance) was not different among the three groups during the basal period. During insulin infusion with euglycemic clamp, whole body glucose utilization (Rd) and endogenous glucose Ra were not different among the three groups during the basal period. During insulin infusion with euglycemic clamp, phenylalanine concentrations in the femoral artery and vein did not change significantly in the postabsorptive state (0–240 min) and during the infusion of a low (LD), intermediate (ID) and high (HD) physiological dose of insulin in one leg. Values are means ± SE. Phenylalanine concentrations in femoral artery and vein and in muscle tissue, net balance, leg Ra, leg Rn, delivery to the leg (Fn), and leg outflow (Fout), transport into (Fmus), α-β shunting (Fv,min), release from proteolysis (Fmus), utilization for protein synthesis, and intracellular availability (IC availability) at baseline and during LD, ID, and HD insulin infusion in a leg. P, significance value for 1-way ANOVA on effect of insulin dose on changes from baseline. Common letter denotes that changes from baseline do not differ between groups (Tukey’s test). *P < 0.05 vs. basal (paired t-test).

Whole body glucose utilization (Rn) and endogenous glucose Rn were not different among the three groups during the basal period. During insulin infusion with euglycemic clamp, glucose Rn increased in a dose-dependent manner (P < 0.01), whereas the endogenous Rn was suppressed in all three groups, with no differences among the groups.

Net leg glucose uptake (net balance) was not different among the groups during the basal period. With insulin infusion net balance increased significantly only in the ID and HD groups (P < 0.01).

Phenylalanine concentrations and enrichments. The average phenylalanine concentrations in the femoral artery and vein and in the muscle are reported in Table 3. During the basal period, phenylalanine concentrations in the femoral artery and vein and in the muscle tissue were not different among the groups. Phenylalanine arterial concentrations slightly but significantly (P < 0.05) decreased in all groups, with significant differences between groups (P < 0.05), the largest change occurring in the HD group. Phenylalanine venous concentrations also decreased significantly in all groups with significant differences between groups (P < 0.05), the smallest change observed in the LD group. The muscle concentrations of free phenylalanine decreased significantly only in HD group.

Phenylalanine enrichments in the femoral artery and vein were at steady state during both sampling periods (Fig. 1). Enrichments in the femoral artery and vein and in the muscle tissue were not different among the groups during the basal period (Fig. 1). With insulin infusion, phenylalanine enrichment in the artery significantly increased in all groups, with no group differences. Phenylalanine enrichment in the vein increased significantly in a dose-dependent manner, with the largest changes occurring in the HD group and the smallest changes occurring in the LD group (P < 0.05). Phenylalanine enrichments in the muscle tissue did not change significantly in any of the groups.

Phenylalanine kinetics. Leg and muscle phenylalanine kinetics are shown in Table 3. All kinetic parameters were not different between groups in the basal period.

Phenylalanine delivery to the leg (Fin) and the release from the leg (Fmus) were not significantly affected by insulin, although Fin tended to increase in the ID group. Phenylalanine net balance increased significantly only in the ID and HD group. Net balance became positive only in the ID group, indicating a shift from net muscle protein loss to net muscle protein deposition in this group. Net balance improved also in the HD group, although it did not reach positive values.

Values are means ± SE. Phenylalanine concentrations in femoral artery and vein and in muscle tissue, net balance, leg Ra, leg Rn, delivery to the leg (Fn), and leg outflow (Fout), transport into (Fmus), α-β shunting (Fv,min), release from proteolysis (Fmus), utilization for protein synthesis, and intracellular availability (IC availability) at baseline and during LD, ID, and HD insulin infusion in a leg. P, significance value for 1-way ANOVA on effect of insulin dose on changes from baseline. Common letter denotes that changes from baseline do not differ between groups (Tukey’s test). *P < 0.05 vs. basal (paired t-test).

Table 3. Leg phenylalanine concentrations and kinetics

<table>
<thead>
<tr>
<th>Phenylalanine concentrations, μmol/l</th>
<th>LD</th>
<th></th>
<th>ID</th>
<th></th>
<th>HD</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Artery</td>
<td>62±5</td>
<td>58±5**</td>
<td>55±2</td>
<td>50±2**</td>
<td>63±5</td>
<td>53±5**</td>
</tr>
<tr>
<td>Vein</td>
<td>68±6</td>
<td>63±6**</td>
<td>60±2</td>
<td>48±3**</td>
<td>70±5</td>
<td>53±6**</td>
</tr>
<tr>
<td>Muscle</td>
<td>101±10</td>
<td>90±7</td>
<td>89±9</td>
<td>82±6</td>
<td>104±9</td>
<td>69±7*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Phenylalanine kinetics, nmol-min⁻¹·100 ml leg volume⁻¹</th>
<th>LD</th>
<th></th>
<th>ID</th>
<th></th>
<th>HD</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Net balance</td>
<td>25±9</td>
<td>14±4*</td>
<td>−22±5</td>
<td>15±4**</td>
<td>−25±6</td>
<td>3±4±b**</td>
</tr>
<tr>
<td>Fn</td>
<td>208±37</td>
<td>168±18</td>
<td>221±25</td>
<td>338±65</td>
<td>221±28</td>
<td>234±13</td>
</tr>
<tr>
<td>Fn</td>
<td>233±44</td>
<td>182±20</td>
<td>243±29</td>
<td>322±63</td>
<td>245±32</td>
<td>237±14</td>
</tr>
<tr>
<td>Leg Rn</td>
<td>65±17</td>
<td>49±8</td>
<td>57±13</td>
<td>56±16</td>
<td>68±9</td>
<td>44±8*</td>
</tr>
<tr>
<td>Leg Rd</td>
<td>41±9</td>
<td>36±7*</td>
<td>35±8</td>
<td>71±19**</td>
<td>43±6</td>
<td>41±7*</td>
</tr>
<tr>
<td>Fmus</td>
<td>147±42</td>
<td>94±20</td>
<td>144±35</td>
<td>158±41</td>
<td>112±19</td>
<td>98±25</td>
</tr>
<tr>
<td>Fv,min</td>
<td>172±49</td>
<td>108±21</td>
<td>166±37</td>
<td>142±38</td>
<td>137±24</td>
<td>101±26</td>
</tr>
<tr>
<td>Fv,α</td>
<td>61±20</td>
<td>73±17</td>
<td>77±28</td>
<td>180±39*</td>
<td>109±24</td>
<td>136±20</td>
</tr>
<tr>
<td>Fv,α</td>
<td>72±18</td>
<td>60±8</td>
<td>63±13</td>
<td>78±19</td>
<td>85±11</td>
<td>68±14</td>
</tr>
<tr>
<td>Fv,m</td>
<td>47±10</td>
<td>47±7</td>
<td>40±8</td>
<td>93±21*</td>
<td>60±8</td>
<td>65±15</td>
</tr>
<tr>
<td>IC availability</td>
<td>219±55</td>
<td>155±23</td>
<td>207±45</td>
<td>235±57</td>
<td>197±26</td>
<td>166±31</td>
</tr>
</tbody>
</table>

Fig. 1. Phenylalanine enrichments in the femoral artery and vein and in the free tissue water in the basal and postabsorptive state (0–240 min) and during the infusion of a low (LD), intermediate (ID) and high (HD) physiological dose of insulin in one leg. Values are means ± SE. *P < 0.05 vs. basal values for arterial and venous enrichments in all groups.
With the two-pool method, the leg $R_a$ decreased significantly with insulin infusion only in the HD group ($P < 0.05$), whereas no significant change was detected in the LD and ID groups. Insulin infusion significantly increased the leg $R_d$ only in the ID group ($P < 0.05$).

With the three-pool model, phenylalanine transport into the muscle ($F_{M,A}$) and out of the muscle ($F_{V,M}$) did not significantly change during insulin infusion in any of the three groups. With insulin infusion, phenylalanine arteriovenous shunting ($F_{V,A}$) increased only in the ID group. Phenylalanine release from proteolysis ($F_{M,O}$) was unaffected by insulin infusion in any of the three groups. Phenylalanine $F_{0,M}$, which is a direct measure of phenylalanine utilization for muscle protein synthesis, increased significantly only in the ID group and remained unchanged in the LD and HD groups. The ID group had a slightly, but not significantly, lower BMI due to a larger, but not significantly, proportion of female subjects. To assess whether the differences between groups could be due to the subjects’ sex or to differences in body composition, we performed an analysis of covariance, using BMI and sex as covariates, and found that $F_{0,M}$ was still significantly higher in the ID group compared with the others.

**Mixed muscle FSR.** The mixed muscle protein FSR (Fig. 2) was not different among the three groups during the basal period. Insulin infusion affected FSR according to the dose ($P < 0.05$); it significantly increased FSR in the ID group and, to a lesser extent, in the HD group, whereas FSR remained unchanged in the LD group.

**Correlations and stepwise regression.** The relative changes above baseline in the rate of protein synthesis ($\Delta F_{0,M}$) were highly associated with the changes in blood flow ($r = 0.79$, $P = 0.0001$) as well as with the changes in phenylalanine delivery to the leg ($r = 0.80$, $P < 0.0001$), phenylalanine transport into the muscle ($F_{M,A}$) ($r = 0.54$, $P = 0.016$), and intracellular phenylalanine availability ($r = 0.76$, $P = 0.0002$; Fig. 3). However, no association was found between the change in protein synthesis and changes in free arterial phenylalanine concentration ($r = 0.03$, $P = 0.92$), free muscle phenylalanine concentration ($r = 0.13$, $P = 0.59$), femoral insulin concentration ($r = -0.23$, $P = 0.34$), or delivery ($r = 0.02$, $P = 0.92$).

The relationships between $\Delta F_{0,M}$ and the concomitant changes in several potentially relevant variables were analyzed using two different stepwise regression models. In the first model, we entered as regressors all variables that could potentially affect muscle protein synthesis regardless of collinearity. With this model we found that $\Delta F_{0,M}$ was significantly associated with changes in $F_{in}$ ($\Delta F_{in}$; $P < 0.0001$), partially associated with changes in phenylalanine concentration in the muscle ($\Delta C_M$; $P = 0.10$), and negatively associated with changes in inward transport ($\Delta F_{M,A}$; $P = 0.0054$). The final regression equation ($R^2 = 0.85$) with this model was:

$$\Delta F_{0,M} = 0.51 + 0.69 \cdot \Delta F_{in} + 0.52 \cdot \Delta C_M - 2.62 \cdot \Delta F_{M,A}$$

However, some potentially meaningful regressors were collinear with others. Thus we developed a second model using only one of the collinear regressors. The choice between collinear regressors was primarily based on ease of measurement and degree of physiological significance. Thus we used blood flow, insulin concentration, phenylalanine arterial concentration, and intracellular phenylalanine availability, and we excluded $F_{in}$ because it was collinear with blood flow, insulin delivery because it was collinear with insulin concentration, $F_{M,A}$ because it was collinear with intracellular phenylalanine availability, and phenylalanine concentration in the muscle because it was collinear with arterial phenylalanine concentration. In the final model, $\Delta F_{0,M}$ was significantly associated with the changes in blood flow ($\Delta BF$; $P = 0.0001$) and intracellular phenylalanine availability ($\Delta ICPhe$; $P = 0.12$), although the latter did not reach the statistical significance. The final regression equation was:

$$\Delta F_{0,M} = 0.62 + 0.78 \cdot \Delta BF + 0.94 \cdot \Delta ICPhe$$

The $R^2$ for this multiple regression model was 0.72.

**DISCUSSION**

The results of our experiment indicate that, in healthy young individuals, isolated physiological hyperinsulinemia can stimulate skeletal muscle protein synthesis provided that it increases blood flow and amino acid delivery to the muscle. Specifically, using the local insulin infusion technique in one leg at three physiological doses in the absence of exogenous amino acid replacement, we found that, whereas the insulin effect on muscle glucose uptake was dose dependent, as expected, its effect on muscle amino acid and protein turnover was more complex and significantly relied on the insulin modulation of blood flow and amino acid delivery and availability.

The lower insulin dose induced a twofold increase in leg insulin concentration and insulin delivery to the leg muscle; yet it did not significantly affect blood flow or the arterial phenylalanine delivery to the leg and did not change either muscle protein synthesis or breakdown; nor did it improve net muscle protein anabolism. Despite a slight decrease in the arterial phenylalanine concentration, the intermediate insulin dose tended to increase phenylalanine delivery via increased blood flow. These changes were associated with a significant increase in muscle protein synthesis, no change in breakdown, and the achievement of a net muscle protein anabolic state, confirming previous reports obtained with similar insulin dose and experimental design (5, 8). Finally, the high insulin dose increased...
blood flow, induced a larger decrease in phenylalanine concentration, and, consequently, did not change phenylalanine delivery. These effects, in turn, did not affect muscle protein synthesis (when the arteriovenous balance methods were used), or they increased it but to a lesser extent than in the intermediate dose group (when the precursor-product model was used) and tended to reduce muscle protein breakdown. As a result, the high dose improved net muscle protein balance, albeit to a lesser extent than the intermediate dose. Interestingly, the change in muscle protein synthesis was predicted mostly by changes in blood flow and phenylalanine availability, both extracellular (delivery to the leg) and intracellular (concentration and intracellular flux), whereas insulin concentrations and delivery did not significantly predict the response of protein synthesis.

All together, these data indicate that, although insulin can directly stimulate initiation of translation (23–25), its stimulatory effect on human skeletal muscle protein synthesis is modulated by increases in muscle perfusion and amino acid delivery and availability for the muscle tissue. When muscle perfusion increases as a consequence of hyperinsulinemia, more tissue is exposed to the nutrients contained in the blood. However, if arterial amino acid concentrations decrease too much (as they did in the HD group), the increase in blood flow may be insufficient to overcome the consequent decline in amino acid delivery. Because amino acids, particularly leucine, can directly stimulate initiation of mRNA translation via pathways partially shared with insulin (2), it is possible that their contribution is necessary for an adequate response of muscle protein synthesis to insulin. From a teleological standpoint, this is not surprising if we consider that insulin is normally secreted during meal absorption, which increases amino acid availability.

Our findings may allow for the reconciliation of the conflicting studies previously published on the effects of insulin on human skeletal muscle protein synthesis (4, 5, 20, 33, 34, 53). In light of the results of the present study, these discrepancies may be explained by differences in muscle amino acid availability, as the studies finding a positive effect of insulin on protein synthesis also reported an increase in amino acid availability.
delivery to the muscle (4, 5, 20, 33, 34, 53). Conversely, those reporting no change or a decrease in protein synthesis also reported a decrease in amino acid concentration and a decrease or no change in amino acid delivery (14, 19, 28, 32, 34). In only one experiment, increased amino acid delivery was not associated with a change in muscle protein synthesis (17). It is possible that this was due to either increased intracellular amino acid recycling, not detectable with the two-pool model employed in that study, and/or the use of the forearm as opposed to the leg as a sampling site, because of the potential differential contribution of skin and/or bone marrow protein turnover to leg and forearm protein turnover.

The considerations above underscore the difficulties encountered when trying to isolate the physiological effects of insulin on skeletal muscle protein turnover apart from the context of a meal. The problem is much more complicated than that offered by the insulin regulation of muscle glucose turnover, because glucose alone cannot significantly stimulate its own utilization, whereas amino acids, particularly leucine, can stimulate muscle protein synthesis by stimulating initiation of translation (2, 41, 42, 52). Thus, when insulin is infused to reach physiological postprandial concentrations, the infusion route is a very important variable, because a systemic infusion will decrease blood amino acid concentrations unless they are replaced by exogenous infusion. On the other hand, a local insulin infusion will not decrease amino acid concentrations unless the dose is large enough to exert systemic effects, as seen in our HD group. Additionally, if a systemic or a large local insulin infusion is chosen, then the decision as to whether or not to concomitantly provide exogenous amino acids during hyperinsulinemia is a crucial step that can significantly affect the outcome of the experiment. Either way, there will be an additional variable to account for: decreased amino acid concentration and delivery or increased amino acid delivery and availability as a result of the exogenous infusion, which may per se increase muscle protein synthesis (7).

Furthermore, the sampling site (leg or forearm) is another critical factor because of the possible differential contribution of the nonmuscle tissues (mostly skin and bone) to each limb protein turnover. Skin protein breakdown is decreased and skin protein synthesis is unaffected by insulin (56), whereas bone marrow proteins are likely to turn over faster than muscle proteins, given the high turnover rate of bone marrow cells, but no data are available on the effects of insulin on these cells. The choice of the model to calculate muscle protein turnover can also significantly affect the conclusions of the study. In our experiment, we used all of the three models available to measure human muscle protein synthesis: the two arteriovenous balance methods [two-pool (54) and three-pool (6) models] and the precursor-product model (47). This decision was made because most earlier studies had been performed using the two-pool arteriovenous balance method (14, 17, 19, 20, 28, 32–34, 53). Thus the use of that method allowed us to compare previous results with ours. However, that method cannot detect increases in intracellular amino acid recycling from breakdown into synthesis because it measures the utilization of plasma amino acids for synthesis and the release in the plasma of amino acids deriving from proteolysis. The three-pool model allows for the measurement of the total synthesis and breakdown rates, including recycling (6), and the precursor-product model provides a measure of the overall effect of the treatment over the entire experimental period.

All three methods indicated that the intermediate insulin dose induced a significant increase in muscle protein synthesis, whereas the low dose did not significantly affect any of the muscle protein metabolic parameters. However, although the precursor-product model indicated that the high insulin dose could stimulate muscle protein synthesis, albeit less than the intermediate dose, both the two-pool and the three-pool models did not confirm this result. This is likely due to the timing of the measurements. The parameters of the two arteriovenous balance models were measured during the last hour of each study period, whereas the FSR was measured over the last 3 h of each period, thus providing an average protein synthesis rate for each incorporation period. We hypothesize that the high insulin dose initially stimulated muscle protein synthesis during the early stages of the infusion period and that by the third hour, when the samples for the arteriovenous balance techniques were collected, this effect had vanished, probably due to the decrease in amino acid concentrations and/or availability. Nonetheless, the overall effect of the higher insulin dose on muscle protein synthesis was less pronounced than that of the intermediate dose and therefore does not contradict the general interpretation of our data. However, further studies on the earlier effects of high insulin infusions on skeletal muscle protein synthesis are warranted. Also, animal data suggest that insulin may exert protein-specific effects (10) that were not earlier effects of high insulin infusions on skeletal muscle protein synthesis apart from the context of a meal. The problem is much more complicated than that offered by the insulin regulation of muscle glucose turnover, because glucose alone cannot significantly stimulate its own utilization, whereas amino acids, particularly leucine, can stimulate muscle protein synthesis by stimulating initiation of translation (2, 41, 42, 52). Thus, when insulin is infused to reach physiological postprandial concentrations, the infusion route is a very important variable, because a systemic infusion will decrease blood amino acid concentrations unless they are replaced by exogenous infusion. On the other hand, a local insulin infusion will not decrease amino acid concentrations unless the dose is large enough to exert systemic effects, as seen in our HD group. Additionally, if a systemic or a large local insulin infusion is chosen, then the decision as to whether or not to concomitantly provide exogenous amino acids during hyperinsulinemia is a crucial step that can significantly affect the outcome of the experiment. Either way, there will be an additional variable to account for: decreased amino acid concentration and delivery or increased amino acid delivery and availability as a result of the exogenous infusion, which may per se increase muscle protein synthesis (7).

Furthermore, the sampling site (leg or forearm) is another critical factor because of the possible differential contribution of the nonmuscle tissues (mostly skin and bone) to each limb protein turnover. Skin protein breakdown is decreased and skin protein synthesis is unaffected by insulin (56), whereas bone marrow proteins are likely to turn over faster than muscle proteins, given the high turnover rate of bone marrow cells, but no data are available on the effects of insulin on these cells. The choice of the model to calculate muscle protein turnover can also significantly affect the conclusions of the study. In our experiment, we used all of the three models available to measure human muscle protein synthesis: the two arteriovenous balance methods [two-pool (54) and three-pool (6) models] and the precursor-product model (47). This decision was made because most earlier studies had been performed using the two-pool arteriovenous balance method (14, 17, 19, 20, 28, 32–34, 53). Thus the use of that method allowed us to compare previous results with ours. However, that method cannot detect increases in intracellular amino acid recycling from breakdown into synthesis because it measures the utilization of plasma amino acids for synthesis and the release in the plasma of amino acids deriving from proteolysis. The three-pool model allows for the measurement of the total synthesis and breakdown rates, including recycling (6), and the precursor-product model provides a measure of the overall effect of the treatment over the entire experimental period.

All three methods indicated that the intermediate insulin dose induced a significant increase in muscle protein synthesis, whereas the low dose did not significantly affect any of the muscle protein metabolic parameters. However, although the precursor-product model indicated that the high insulin dose could stimulate muscle protein synthesis, albeit less than the intermediate dose, both the two-pool and the three-pool models did not confirm this result. This is likely due to the timing of the measurements. The parameters of the two arteriovenous balance models were measured during the last hour of each study period, whereas the FSR was measured over the last 3 h of each period, thus providing an average protein synthesis rate for each incorporation period. We hypothesize that the high insulin dose initially stimulated muscle protein synthesis during the early stages of the infusion period and that by the third hour, when the samples for the arteriovenous balance techniques were collected, this effect had vanished, probably due to the decrease in amino acid concentrations and/or availability. Nonetheless, the overall effect of the higher insulin dose on muscle protein synthesis was less pronounced than that of the intermediate dose and therefore does not contradict the general interpretation of our data. However, further studies on the earlier effects of high insulin infusions on skeletal muscle protein synthesis are warranted. Also, animal data suggest that insulin may exert protein-specific effects (10) that were not
ACKNOWLEDGMENTS

We thank Jeanine Cordero for technical assistance, the study volunteers for their patience and dedication, and all the nurses and personnel of the General Clinical Research Center of the University of Southern California for help with the conduct of the clinical portion of this study.

GRANTS

This study was supported by National Institutes of Health Grants R01-AG-18311 from the National Institute on Aging, S10-RR-16650 from the Shared Instrumentation Grant Program, National Center for Research Resources, and M01-RR-43 from the General Clinical Research Branch, National Center for Research Resources.

REFERENCES


37. Sinaud S, Balage M, Bayle G, Dardevet D, Vary TC, Kimball SR, Jefferson LS, and Grizard J. Diazoxide-induced insulin deficiency...
greatly reduced muscle protein synthesis in rats: involvement of eIF4E. 


